David Lebowitz
Stock Analyst at Citigroup
(2.32)
# 2,470
Out of 4,784 analysts
108
Total ratings
42.86%
Success rate
-1.69%
Average return
Main Sectors:
Stocks Rated by David Lebowitz
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PLRX Pliant Therapeutics | Maintains: Neutral | $4 → $1.5 | $1.47 | +2.04% | 6 | Mar 4, 2025 | |
| NTLA Intellia Therapeutics | Maintains: Neutral | $12 → $14 | $8.07 | +73.48% | 7 | Feb 28, 2025 | |
| BBIO BridgeBio Pharma | Maintains: Buy | $45 → $49 | $35.11 | +39.56% | 3 | Feb 21, 2025 | |
| IONS Ionis Pharmaceuticals | Maintains: Buy | $67 → $64 | $31.15 | +105.46% | 12 | Feb 20, 2025 | |
| EXEL Exelixis | Maintains: Buy | $38 → $45 | $36.70 | +22.62% | 2 | Feb 12, 2025 | |
| PTCT PTC Therapeutics | Maintains: Sell | $32 → $45 | $54.24 | -17.04% | 4 | Feb 12, 2025 | |
| INCY Incyte | Maintains: Buy | $97 → $88 | $60.60 | +45.21% | 5 | Feb 11, 2025 | |
| VKTX Viking Therapeutics | Initiates: Neutral | $38 | $25.65 | +48.15% | 1 | Feb 7, 2025 | |
| CYTK Cytokinetics | Initiates: Buy | $86 | $43.19 | +99.12% | 1 | Feb 7, 2025 | |
| MIRM Mirum Pharmaceuticals | Maintains: Buy | $65 → $68 | $45.99 | +47.86% | 4 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $70 | $19.93 | +251.23% | 1 | Oct 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $13 → $15 | $6.48 | +131.48% | 3 | Sep 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $178 → $207 | $154.68 | +33.82% | 12 | Sep 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $65 → $76 | $88.72 | -14.34% | 5 | May 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $39 → $37 | $19.96 | +85.37% | 9 | May 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $382 | $327.87 | +16.51% | 1 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $103 → $96 | $71.44 | +34.38% | 3 | Jun 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $18 → $12 | $1.64 | +631.71% | 2 | Jul 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $170 → $164 | $268.46 | -38.91% | 7 | Jul 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $36 → $39 | $15.73 | +147.93% | 6 | Jun 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $20 → $21 | $13.18 | +59.33% | 11 | Oct 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $435 → $405 | $4.16 | +9,635.58% | 1 | Oct 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $13 → $14 | $1.41 | +892.91% | 2 | Oct 12, 2021 |
Pliant Therapeutics
Mar 4, 2025
Maintains: Neutral
Price Target: $4 → $1.5
Current: $1.47
Upside: +2.04%
Intellia Therapeutics
Feb 28, 2025
Maintains: Neutral
Price Target: $12 → $14
Current: $8.07
Upside: +73.48%
BridgeBio Pharma
Feb 21, 2025
Maintains: Buy
Price Target: $45 → $49
Current: $35.11
Upside: +39.56%
Ionis Pharmaceuticals
Feb 20, 2025
Maintains: Buy
Price Target: $67 → $64
Current: $31.15
Upside: +105.46%
Exelixis
Feb 12, 2025
Maintains: Buy
Price Target: $38 → $45
Current: $36.70
Upside: +22.62%
PTC Therapeutics
Feb 12, 2025
Maintains: Sell
Price Target: $32 → $45
Current: $54.24
Upside: -17.04%
Incyte
Feb 11, 2025
Maintains: Buy
Price Target: $97 → $88
Current: $60.60
Upside: +45.21%
Viking Therapeutics
Feb 7, 2025
Initiates: Neutral
Price Target: $38
Current: $25.65
Upside: +48.15%
Cytokinetics
Feb 7, 2025
Initiates: Buy
Price Target: $86
Current: $43.19
Upside: +99.12%
Mirum Pharmaceuticals
Nov 13, 2024
Maintains: Buy
Price Target: $65 → $68
Current: $45.99
Upside: +47.86%
Oct 7, 2024
Initiates: Buy
Price Target: $70
Current: $19.93
Upside: +251.23%
Sep 24, 2024
Maintains: Buy
Price Target: $13 → $15
Current: $6.48
Upside: +131.48%
Sep 17, 2024
Maintains: Buy
Price Target: $178 → $207
Current: $154.68
Upside: +33.82%
May 3, 2024
Maintains: Sell
Price Target: $65 → $76
Current: $88.72
Upside: -14.34%
May 2, 2024
Maintains: Buy
Price Target: $39 → $37
Current: $19.96
Upside: +85.37%
Mar 6, 2024
Initiates: Buy
Price Target: $382
Current: $327.87
Upside: +16.51%
Jun 30, 2023
Maintains: Neutral
Price Target: $103 → $96
Current: $71.44
Upside: +34.38%
Jul 15, 2022
Maintains: Equal-Weight
Price Target: $18 → $12
Current: $1.64
Upside: +631.71%
Jul 15, 2022
Maintains: Equal-Weight
Price Target: $170 → $164
Current: $268.46
Upside: -38.91%
Jun 7, 2022
Maintains: Overweight
Price Target: $36 → $39
Current: $15.73
Upside: +147.93%
Oct 12, 2021
Maintains: Equal-Weight
Price Target: $20 → $21
Current: $13.18
Upside: +59.33%
Oct 12, 2021
Maintains: Overweight
Price Target: $435 → $405
Current: $4.16
Upside: +9,635.58%
Oct 12, 2021
Maintains: Equal-Weight
Price Target: $13 → $14
Current: $1.41
Upside: +892.91%